MEDI6469
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for MEDI6469, covering 2017-05-08 to 2017-05-08. Get the full timeline:
Most recent: Clinical Trial Update: A Phase 1b/2 Safety and Tolerability Study of MEDI6469 in Combination With Therapeutic Immune Agents or Monoclonal Antibodies [Phase 1, Phase 2]